$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000140191424000033 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$22.44K	$9.302K	$0.00
YoY Change
Cost Of Revenue	$0.00	$7.670K
YoY Change
Gross Profit	$22.44K	$1.630K
YoY Change
Gross Profit Margin	100.01%	17.52%
Selling, General & Admin	$2.473M	$2.696M	$3.362M
YoY Change	-16.04%	-19.83%	29.57%
% of Gross Profit	11021.08%	165373.01%
Research & Development	$4.909M	$3.329M	$5.020M
YoY Change	-18.78%	-33.7%	-13.53%
% of Gross Profit	21875.11%	204203.68%
Depreciation & Amortization	$15.44K	$10.78K	$9.508K
YoY Change	60.67%	13.36%	81.9%
% of Gross Profit	68.81%	661.23%
Operating Expenses	$7.382M	$6.032M	$8.383M
YoY Change	-17.88%	-28.04%	-0.21%
Operating Profit	-$7.359M	-$6.022M	-$8.383M
YoY Change	-18.13%	-28.16%	-0.21%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$109.3K	-$732.9K	$340.1K
YoY Change	-148.1%	-315.46%	19020.18%
Pretax Income	$12.91M	-$6.755M	-$8.043M
YoY Change	-247.34%	-16.0%	-4.24%
Income Tax
% Of Pretax Income
Net Earnings	$12.91M	-$6.800M	-$8.000M
YoY Change	-247.34%	-15.0%	-4.76%
Net Earnings / Revenue	57539.25%	-73102.56%
Basic Earnings Per Share	$1.53	-$0.07	-$0.09
Diluted Earnings Per Share	$1.52	-$0.07	-$0.09
COMMON SHARES
Basic Shares Outstanding	101.1M shares	100.6M shares	86.18M shares
Diluted Shares Outstanding	8.476M shares	100.5M shares	85.52M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.41M	$3.631M	$19.83M
YoY Change	23.15%	-81.69%	-49.57%
Cash & Equivalents	$16.40M	$3.600M	$19.83M
Short-Term Investments
Other Short-Term Assets	$3.512M	$152.2K	$201.4K
YoY Change	1190.81%	-24.42%	-97.03%
Inventory
Prepaid Expenses	$3.512M	$4.814M	$7.082M
Receivables
Other Receivables	$902.2K	$1.386M	$2.399M
Total Short-Term Assets	$20.83M	$9.983M	$29.51M
YoY Change	-6.36%	-66.17%	-38.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$322.3K	$52.49K	$55.40K
YoY Change	603.91%	-5.25%	118.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$528.6K	$654.5K	$799.3K
YoY Change	-42.6%	-18.11%	-40.53%
Total Long-Term Assets	$2.777M	$3.030M	$854.7K
YoY Change	187.25%	254.52%	-37.58%
TOTAL ASSETS
Total Short-Term Assets	$20.83M	$9.983M	$29.51M
Total Long-Term Assets	$2.777M	$3.030M	$854.7K
Total Assets	$23.61M	$13.01M	$30.37M
YoY Change	1.71%	-57.15%	-38.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.910M	$4.041M	$2.696M
YoY Change	-70.8%	49.89%	-4.78%
Accrued Expenses	$1.254M	$1.370M	$5.480M
YoY Change	-70.09%	-74.99%	54.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.59M	$17.72M	$24.34M
YoY Change	-40.93%	-27.17%	48.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.345M	$6.287M	$1.057M
YoY Change	416.45%	494.74%	-44.74%
Total Long-Term Liabilities	$6.345M	$6.287M	$1.057M
YoY Change	416.45%	494.74%	-44.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.59M	$17.72M	$24.34M
Total Long-Term Liabilities	$6.345M	$6.287M	$1.057M
Total Liabilities	$20.93M	$24.01M	$25.40M
YoY Change	-19.26%	-5.45%	38.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$165.1M	-$178.0M	-$149.1M
YoY Change	4.56%	19.38%	25.82%
Common Stock	$168.1M	$167.4M	$154.5M
YoY Change	8.08%	8.37%	3.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.672M	-$11.00M	$4.972M
YoY Change
Total Liabilities & Shareholders Equity	$23.61M	$13.01M	$30.37M
YoY Change	1.71%	-57.15%	-38.26%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$12.91M	-$6.800M	-$8.000M
YoY Change	-247.34%	-15.0%	-4.76%
Depreciation, Depletion And Amortization	$15.44K	$10.78K	$9.508K
YoY Change	60.67%	13.36%	81.9%
Cash From Operating Activities	$12.90M	-$6.813M	-$16.12M
YoY Change	-295.93%	-57.73%	30.58%
INVESTING ACTIVITIES
Capital Expenditures	$285.2K	$7.296K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$285.2K	-$7.296K	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	115.4K	$14.03K	$1.299M
YoY Change	-74.49%	-98.92%
NET CHANGE
Cash From Operating Activities	12.90M	-$6.813M	-$16.12M
Cash From Investing Activities	-285.2K	-$7.296K	$0.00
Cash From Financing Activities	115.4K	$14.03K	$1.299M
Net Change In Cash	12.73M	-$6.845M	-$14.84M
YoY Change	-307.61%	-53.87%	20.09%
FREE CASH FLOW
Cash From Operating Activities	$12.90M	-$6.813M	-$16.12M
Capital Expenditures	$285.2K	$7.296K	$0.00
Free Cash Flow	$12.62M	-$6.820M	-$16.12M
YoY Change	-291.6%	-57.68%	30.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	13737154	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	470390	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	468726	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17724909	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20480436	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-39227	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22005	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6794583	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8064506	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85517540	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85517540	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5047640	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8042501	usd
CY2024Q1	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	1901283	usd
CY2023Q1	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	2477198	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6812962	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16117571	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7296	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7296	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2024Q1	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	215113	usd
CY2023Q1	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
CY2024Q1	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
CY2023Q1	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1299375	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10811056	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34669605	usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4139823
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3655 Nobel Drive
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 260
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	926-7655
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92122
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2024Q1	dei	Trading Symbol TradingSymbol	DARE
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	101092900	shares
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	152204	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	0	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	9982561	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	17543539	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52493	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	655975	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3337426	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3328520	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5020223	usd
CY2024Q1	dare	License Fee Expense LicenseFeeExpense	25000	usd
CY2023Q1	dare	License Fee Expense LicenseFeeExpense	25000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11112110	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	624621	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1299375	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8042501	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22005	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4971600	usd
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	DARÉ BIOSCIENCE, INC.
CY2024Q1	dei	City Area Code CityAreaCode	858
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	762432	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1163477	usd
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001401914
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#LicenseMember
CY2024Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#RoyaltyMember
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1560706	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1319630	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	654530	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	599594	usd
CY2024Q1	us-gaap	Assets Assets	13012722	usd
CY2023Q4	us-gaap	Assets Assets	21282215	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4040509	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3385551	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1370465	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2889005	usd
CY2024Q1	dare	Royalties Payable Current RoyaltiesPayableCurrent	7674	usd
CY2023Q4	dare	Royalties Payable Current RoyaltiesPayableCurrent	0	usd
CY2024Q1	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	11835871	usd
CY2024Q1	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	4115631	usd
CY2023Q4	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	3913676	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1171592	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	935743	usd
CY2024Q1	us-gaap	Liabilities Liabilities	24012132	usd
CY2023Q4	us-gaap	Liabilities Liabilities	26329855	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100581900	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100581900	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99973932	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99973932	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	10058	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9997	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-400123	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-360896	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	167382042	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	166539290	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177991387	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171236031	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-10999410	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5047640	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13012722	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21282215	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2670581	usd
CY2024Q1	us-gaap	Royalty Expense RoyaltyExpense	7674	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	6031775	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	8382649	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6022473	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8382649	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-732883	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	340148	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6755356	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8042501	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100514272	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100514272	shares
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	627700	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	215113	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6755356	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-39227	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-10999410	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6755356	usd
CY2024Q1	us-gaap	Depreciation Depreciation	10778	usd
CY2023Q1	us-gaap	Depreciation Depreciation	9508	usd
CY2024Q1	dare	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-117239	usd
CY2023Q1	dare	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-89940	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	627700	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	624621	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-600000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2024Q1	dare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	85432	usd
CY2023Q1	dare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	67644	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	368817	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	695548	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1304190	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	416464	usd
CY2024Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-401045	usd
CY2023Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	152204	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	201385	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	54936	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	166545	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-120802	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-95846	usd
CY2024Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	654958	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	667661	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1318149	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5413814	usd
CY2024Q1	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	7674	usd
CY2023Q1	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	117213	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2024Q1	dare	Repayment Of Liability On Sale Future Royalties RepaymentOfLiabilityOnSaleFutureRoyalties	690	usd
CY2023Q1	dare	Repayment Of Liability On Sale Future Royalties RepaymentOfLiabilityOnSaleFutureRoyalties	0	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	200391	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14032	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1299375	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-39227	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-22005	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6845453	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14840201	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3965603	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19829404	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3630603	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19744404	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	335000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	85000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3965603	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19829404	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	358315	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	300000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3600000	usd
CY2024Q1	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	11800000	usd
CY2024Q1	dare	Working Capital Increase Deficit WorkingCapitalIncreaseDeficit	-7700000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6800000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6800000	usd
CY2024Q1	dare	Periodof Insufficient Cashand Liquidity Requirements PeriodofInsufficientCashandLiquidityRequirements	P12M
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	usd
CY2024Q1	dare	Milestone Payment Revenues MilestonePaymentRevenues	1800000	usd
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2018Q1	dare	Estimated Fair Value Of Warrants Recorded In Equity EstimatedFairValueOfWarrantsRecordedInEquity	3000000	usd
CY2019Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.98
CY2020Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.96
CY2024Q1	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	4500000	usd
CY2024Q1	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y3M3D
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2024Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	400000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1600000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	139000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	159000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	105000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M1D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1050
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	456000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	660000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	680000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	130000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1926000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	284000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1642000	usd
CY2023Q3	dare	Insurance Financing Premiums Taxes And Fees Amount InsuranceFinancingPremiumsTaxesAndFeesAmount	600000	usd
CY2023Q3	dare	Insurance Financing Interest Rate InsuranceFinancingInterestRate	0.080
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	67000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26883213	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9116719	shares
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
dare-20240331_cal.xml	Edgar Link	unprocessable
0001401914-24-000033-index-headers.html	Edgar Link	pending
0001401914-24-000033-index.html	Edgar Link	pending
0001401914-24-000033.txt	Edgar Link	pending
0001401914-24-000033-xbrl.zip	Edgar Link	pending
dare-20240331.htm	Edgar Link	pending
dare-20240331.xsd	Edgar Link	pending
dare-20240331_g1.jpg	Edgar Link	pending
dare-arbylawsjan20234856.htm	Edgar Link	pending
dare-arbylawsjan20234856001.jpg	Edgar Link	pending
dare-arbylawsjan20234856002.jpg	Edgar Link	pending
dare-arbylawsjan20234856003.jpg	Edgar Link	pending
dare-arbylawsjan20234856004.jpg	Edgar Link	pending
dare-arbylawsjan20234856005.jpg	Edgar Link	pending
dare-arbylawsjan20234856006.jpg	Edgar Link	pending
dare-arbylawsjan20234856007.jpg	Edgar Link	pending
dare-arbylawsjan20234856008.jpg	Edgar Link	pending
dare-arbylawsjan20234856009.jpg	Edgar Link	pending
dare-arbylawsjan20234856010.jpg	Edgar Link	pending
dare-arbylawsjan20234856011.jpg	Edgar Link	pending
dare-arbylawsjan20234856012.jpg	Edgar Link	pending
dare-arbylawsjan20234856013.jpg	Edgar Link	pending
dare-arbylawsjan20234856014.jpg	Edgar Link	pending
dare-arbylawsjan20234856015.jpg	Edgar Link	pending
dare-arbylawsjan20234856016.jpg	Edgar Link	pending
dare-arbylawsjan20234856017.jpg	Edgar Link	pending
dare-arbylawsjan20234856018.jpg	Edgar Link	pending
dare-arbylawsjan20234856019.jpg	Edgar Link	pending
dare-arbylawsjan20234856020.jpg	Edgar Link	pending
dare-arbylawsjan20234856021.jpg	Edgar Link	pending
exhibit101_consultingagree.htm	Edgar Link	pending
exhibit311_20240331.htm	Edgar Link	pending
exhibit321_20240331.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
dare-20240331_def.xml	Edgar Link	unprocessable
dare-20240331_lab.xml	Edgar Link	unprocessable
dare-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dare-20240331_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2024 Q2 Form 10-Q Financial Statement

#000140191424000033 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2024 Q2 Form 10-Q Financial Statement

#000140191424000033 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare